CLINICAL TRIALS PROFILE FOR TAPINAROF
✉ Email this page to a colleague
All Clinical Trials for TAPINAROF
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03956355 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) | Completed | IQVIA Biotech | Phase 3 | 2019-05-21 | This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks. |
| NCT03956355 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) | Completed | Dermavant Sciences GmbH | Phase 3 | 2019-05-21 | This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks. |
| NCT03983980 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) | Completed | IQVIA Biotech | Phase 3 | 2019-06-06 | This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks. |
| NCT03983980 ↗ | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) | Completed | Dermavant Sciences GmbH | Phase 3 | 2019-06-06 | This is a randomized double-blind vehicle-controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks. |
| NCT04042103 ↗ | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis | Completed | Dermavant Sciences GmbH | Phase 2 | 2019-07-23 | This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis. |
| NCT04053387 ↗ | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) | Completed | IQVIA Biotech | Phase 3 | 2019-08-13 | This is a long-term, open-label, multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in adults with plaque psoriasis. Subjects in this study completed treatment in 1 of 2 Phase 3 pivotal efficacy and safety studies (Study DMVT-505-3001 or Study DMVT-505-3002). This study will consist of up to 40 weeks of treatment and a 4-week safety follow-up period. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAPINAROF
Condition Name
Clinical Trial Locations for TAPINAROF
Trials by Country
Clinical Trial Progress for TAPINAROF
Clinical Trial Phase
Clinical Trial Sponsors for TAPINAROF
Sponsor Name
